Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) selectively and reversibly inhibit sodium-glucose cotransporter-2 (SGLT2), promoting renal glucose excretion and reducing plasma glycaemia. By increasing renal glucose excretion, these drugs favour a negative energy balance, leading to weight loss. Their glucoselowering effect is independent of insulin. Although these drugs have only recently been developed, they have been included in all the main national and international guidelines since 2014. The present review summarises the most important recommendations on the use of SGLT2 in patients with DM2 contained in the most recently published guidelines and consensus statements.

Keywords: American College of Endocrinology and American Association of Clinical Endocrinologists (ACE/AACE); American College of Endocrinology y American Association of Clinical Endocrinologists (ACE/ AACE).; American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD); American Diabetes Association y European Association for the Study of Diabetes (ADA-EASD); Atención Primaria de la Salud (redGDPS); Canagliflozin; Canagliflozina; Clinical practice guidelines (CPG); Cotransportador sodio-glucosa tipo 2 (SGLT2); Dapagliflozin; Dapagliflozina; Diabetes mellitus tipo 2 (DM2); Empagliflozin; Empagliflozina; Guías de práctica clínica; Inhibidores del SGLT2 (iSGLT2); Network of Working Groups for the Study of Diabetes in Primary Health Care (redGDPS); Red de Grupos de Estudio de la Diabetes en; SGLT2 inhibitors (SGLT2-i); Sodium-glucose cotransporter 2 (SGLT2); Type 2 diabetes mellitus (DM2).